Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous allo-APZ2-OTS in epidermolysis bullosa
MOH_2023-09-11_012850Phase 3Not yet recruiting
- Sponsor
- RHEACELL
- Start
- Feb 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of EBESANAR in epidermolysis bullosa (EB), Recessive Dystrophic Epidermolysis Bullosa (RDEB) and junctional epidermolysis bullosa (JEB) (3 arms), sponsored by RHEACELL. Primary endpoint: Primary endpoint not reported. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
EBESANAR
03
Conditions
epidermolysis bullosa (EB)Recessive Dystrophic Epidermolysis Bullosa (RDEB)junctional epidermolysis bullosa (JEB)
Beyond the preview
Go deeper on MOH_2023-09-11_012850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-11_012850.